(Q37953969)

25 August 2017

title

Drug safety evaluation of intravitreal triamcinolone acetonide (English)

1 reference

25 August 2017

Daniele Veritti

1

1 reference

25 August 2017

Andrea Di Giulio

series ordinal

2

1 reference

25 August 2017

Valentina Sarao

series ordinal

3

1 reference

25 August 2017

Paolo Lanzetta

series ordinal

4

1 reference

25 August 2017

language of work or name

English

0 references

publication date

9 November 2011

1 reference

Expert Opinion on Drug Safety

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

331-340

1 reference

Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Neovascular glaucoma treated by intravitreal triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone acetonide as treatment for extensive exudative retinal detachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal Triamcinolone for Radiation-Induced Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Controversies in intravitreal triamcinolone acetonide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Serum levels of triamcinolone acetonide after intravitreal injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Triamcinolone acetonide and dexamethasome suppress TNF-alpha-induced histone H4 acetylation on lysine residues 8 and 12 in mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Effects of periocular administration of triamcinolone acetonide on leukocyte-endothelium interactions in the ischemic retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone as a primary therapy in diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Chronic prephthisical ocular hypotony treated by intravitreal triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Reducing the risk of endophthalmitis following intravitreal injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Retinal progenitor cells in the posterior pars plana of rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone acetonide Complication of infectious and sterile endophthalmitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Acute endophthalmitis following intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone and endophthalmitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Acute endophthalmitis incidence: intravitreal triamcinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Pseudo-endophthalmitis after intravitreal injection of triamcinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Noninfectious endophthalmitis associated with intravitreal triamcinolone injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intraocular pressure elevation after intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intraocular pressure after intravitreal injection of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Safety of intravitreal high-dose reinjections of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Complications of intravitreal injection of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone acetonide and intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Removal of the intruding Miragel's scleral buckle by pars plana ultrasonic fragmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Ocular side effects and complications of intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Central serous chorioretinopathy and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Evaluation of toxicity due to vital stains in isolated rat retinas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

RETINAL TOXICITY OF INTRAVITREAL KENALOG IN ALBINO RABBITS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.635141

10.1517/14740338.2012.635141

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference